Puma Biotechnology, Inc.

Name: Puma Biotechnology, Inc. standardized financial statements, quarterly
Creator: Listed

PBYINasdaqCIK 1401667HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$56.5m, Q2 FY2026

Operating income$7.6m, Q2 FY2026

Net income$8.2m, Q2 FY2026

Puma Biotechnology, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	56.1	72.2	43.8	47.1	80.5	59.1	46.0	52.4	54.5	75.5	44.8	56.5
Cost of revenue	$m	13.3	24.3	10.7	10.7	29.1	13.9	10.6	12.3	12.2	23.1	10.4	12.5
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Selling, general and administrative	$m	22.8	20.2	21.8	25.0	16.8	16.6	17.6	18.0	16.8	18.4	18.4	17.5
Operating income	$m	8.6	14.8	(2.3)	(2.2)	22.1	13.4	4.0	6.6	9.6	17.1	(3.8)	7.6
Interest expense	$m	3.3	3.4	3.4	3.4	3.1	2.6	2.2	1.8	1.5	1.1	0.7	0.2
Income tax	$m	0.2	0.5	0.2	0.4	0.3	(7.1)	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$m	5.8	12.3	(4.8)	(4.5)	20.3	19.3	3.0	5.9	8.8	13.4	(3.8)	8.2
Diluted EPS	$ per share	0.12	not reported	(0.10)	(0.09)	0.41	not reported	0.06	0.12	0.17	not reported	(0.07)	0.16
Basic EPS	$ per share	0.12	not reported	(0.10)	(0.09)	0.41	not reported	0.06	0.12	0.18	not reported	(0.07)	0.16

Balance sheet

Cash and equivalents$36.5m, Q2 FY2026

Long-term debt$0, Q2 FY2026

Shareholders' equity$138.5m, Q2 FY2026

Puma Biotechnology, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	81.8	84.6	76.8	67.1	67.3	69.2	63.0	54.7	53.5	29.6	36.2	36.5
Current assets	$m	125	156	143	138	157	148	133	137	144	163	142	145
Total assets	$m	204	231	214	205	221	213	196	195	203	216	193	193
Current liabilities	$m	67.4	99.4	98.2	104	110	96.1	86.7	79.1	82.7	81.3	59.7	49.8
Total liabilities	$m	165	177	163	156	150	121	99.1	90.2	87.6	86.0	64.3	54.2
Long-term debt	$m	76.6	65.7	54.7	43.7	32.7	21.7	10.6	10.9	0.0	0.0	0.0	0.0
Current portion of debt	$m	22.7	34.0	45.3	45.3	45.3	45.3	45.3	34.0	33.7	22.5	11.3	0.0
Shareholders' equity	$m	38.7	53.4	51.0	48.5	71.1	92.1	97.1	105	115	130	128	139

Cash flow

Operating cash flow$1.6m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

Puma Biotechnology, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	10.6	10.5	11.2	1.0	11.0	15.6	3.6	14.1	9.7	14.4	15.4	1.6
Capital expenditure	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	(0.0)	0.0	0.0

Diluted shares (weighted)52.60m, Q2 FY2026

Puma Biotechnology, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	45.6	47.2	47.2	47.8	48.2	48.3	49.2	49.9	50.1	50.9	50.8	52.6

Shares outstanding: 51.62m at Aug 3, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.